Lyell Immunopharma Inc. (LYEL)
0.65
-0.06 (-8.55%)
At close: Mar 03, 2025, 11:35 AM
No 1D chart data available
| Bid | 0.64 |
| Market Cap | 190.52M |
| Revenue (ttm) | 71.81K |
| Net Income (ttm) | -232.52M |
| EPS (ttm) | -0.79 |
| PE Ratio (ttm) | -0.83 |
| Forward PE | -1.35 |
| Analyst | Hold |
| Ask | 0.65 |
| Volume | 239,790 |
| Avg. Volume (20D) | 1,202,824 |
| Open | 0.70 |
| Previous Close | 0.71 |
| Day's Range | 0.65 - 0.70 |
| 52-Week Range | 0.51 - 3.26 |
| Beta | -0.36 |
About LYEL
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 2021
Employees 224
Stock Exchange NASDAQ
Ticker Symbol LYEL
Website https://www.lyell.com
Analyst Forecast
According to 2 analyst ratings, the average rating for LYEL stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 53.35% from the latest price.
Buy 0.00%
Hold 50.00%
Sell 50.00%
3 months ago
+19.35%
Lyell Immunopharma shares are trading higher. The ...
Unlock content with
Pro Subscription
4 months ago
-5.22%
Lyell Immunopharma shares are trading higher after the company announced it will acquire privately-owned clinical-stage biotechnology company ImmPACT Bio.
